Nabil Ismaili, Director of Medical Oncology and Radiotherapy Department at Mohammed VI University of Sciences and Health , shared a post on LinkedIn:

“Major Advances in Gynecologic Oncology in 2025,

This work synthesizes the most impactful clinical trial data presented at ASCO 2025 and ESMO 2025, highlighting paradigm-shifting advances across cervical, ovarian, and endometrial cancers.

Key takeaways from the 2025 landscape:

Cervical Cancer:
– Curative-intent Immunotherapy: The KEYNOTE-A18 trial establishes pembrolizumab + chemoradiotherapy (CRT) as a new standard for high-risk locally advanced disease.
– Metastatic Options: Novel combinations like Camrelizumab + Famitinib offer chemotherapy-free alternatives.
– Dynamic Monitoring: ctDNA-guided strategies from the CALLA trial are redefining risk stratification and response assessment.

Ovarian Cancer:
– Breaking the Platinum-Resistant Barrier: The KEYNOTE-B96 trial shows the first significant overall survival benefit with pembrolizumab + weekly paclitaxel in platinum-resistant recurrent ovarian cancer.
– Novel Mechanisms: The ROSELLA trial introduces relacorilant (a glucocorticoid receptor modulator) as a new weapon against resistance.
– Next-Generation ADCs: REJOICE-Ovarian01 demonstrates remarkable activity with R-DXd, a CDH6-targeting antibody-drug conjugate.
– Chemotherapy Optimization: ICON8B confirms the value of dose-dense chemotherapy in high-risk patients.

Endometrial Cancer:
– Biomarker-driven therapy is now the standard, with MMR status guiding first-line immuno-chemotherapy decisions.

This review provides a comprehensive, evidence-based framework for updating clinical practice and highlights the ongoing evolution toward more personalized and effective care in gynecologic oncology.”

Nabil Ismaili